Why Medicine Costs So Much Money, Despite Imports from Low-Cost Nations
The Senate Commerce Committee takes the little known, and even less understood, Pharmacy Benefit Manager industry to task for high drug costs.
Supply Chain Dependence Makes Reshoring Harder – McKinsey
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
Repealing China’s Most Favored Nation Status: A Guide
By Charles Benoit, CPA Trade Counsel In December, the U.S.-China Commission, a group created by Congress to advise on managing the bilateral relationship, formally recommended that China lose its Most-Favored Nation (MFN) tariff status. Referencing the decision to grant China permanent MFN status in 2001, Speaker McCarthy said in remarks on the House floor yesterday…
November Trade Deficit Falls 21% to $61.5 Billion, But $1 Trillion-Plus Deficit Record Beat
The November trade deficit fell, but that didn’t stop the U.S. from record imports this year. The goods deficit is now over $1.1 trillion.
Senate Hearing Bemoans Worker Shortages, Wonders If Reshoring Can Work
A Senate Commerce subcommittee hearing heard from witnesses who said worker shortages will ultimately be a drag on U.S. reshoring efforts. Pharmaceutical reps warned of high energy costs, which could add to import dependence.
CPA Debates: What’s So Great About Free Trade?
CPA chief economist Jeff Ferry took on a Pepperdine University free trader in a firey debate this week.
September Trade Deficit Rises 11.6% As U.S. Heads For Record $1.1+ Trillion Goods Deficit
After a sharp six month decline, the trade deficit is back up and on track to break another record even as China imports stall.
U.S. Dependent on Foreign Sources for Nearly Every Critical Mineral
The U.S. is largely dependent on foreign sources for the critical minerals that will power a clean energy transition. The Inflation Act helps. But it’s going to take a while to be even moderately self-sufficient.
“Globalization is (Almost) Dead” – New Book by FT Columnist Rana Foroohar Explains Why
Financial Times columnist Rana Foroohar writes about the end times for globalization as we know. What comes next in the post-global world?
China’s Five-Year Plan for Biotech Making it Increasingly Attractive for Global Pharma
The China pharmaceutical industry is taking a multi-pronged approach to becoming a dominant player in Asia. Maybe even the world.